503A pharmacies and 503B facilities: roles and differences
503A and 503B are different legal frameworks. Neither label by itself guarantees product quality, and neither makes a compounded preparation FDA-approved.
The 503A role
Section 503A describes conditions under which a licensed pharmacist or physician may compound certain drugs that qualify for specific exemptions. A prescription for an identified patient is central. There are also limits on copies of commercially available products.
If a significant difference from a commercial product is relied on, the prescriber determines and documents that difference for the patient. A different dose, concentration, or ingredient should not be presented as automatic permission.
The 503B role
A 503B outsourcing facility registers with FDA and operates under a different federal framework. It may prepare certain products for distribution without first receiving an individual prescription, subject to specific conditions. Registration is not approval of the facility or each product.
Hold us to this standard
Every check on this page is one you can run on New Hope
Care starts with a $119 review of your history and contraindications by Dr. Anjmun Sharma, MD. If a prescription is appropriate, we name the dispensing pharmacy so you can verify its license before fulfillment, and we say plainly that compounded semaglutide is not FDA-approved, not brand-identical, and that results vary.
See if you are a candidate, free 2-minute quizPractical comparison
| Question | 503A | 503B |
|---|---|---|
| Primary focus | Prescription for an identified patient. | Registered outsourcing facility. |
| Oversight | State pharmacy board has a primary role, with applicable federal requirements. | FDA and state authorities have oversight roles. |
| Product approval | Not FDA-approved. | Not FDA-approved. |
| Verification | State license, public discipline, and prescription details. | FDA registration and public inspection records, plus state requirements. |
How to verify without assuming
- Ask for the legal name of the entity that would prepare or dispense.
- Check its license and any public disciplinary action.
- Confirm whether it claims 503A operation or 503B registration.
- Ask what documentation accompanies the exact prescription. Practices vary.
Expanded decision guide
The short version
Section 503A applies to qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, with an individual-patient prescription among its core conditions. Section 503B applies to registered outsourcing facilities, where compounding is by or under the direct supervision of a licensed pharmacist and may occur with or without patient-specific prescriptions when all statutory conditions are met. A 503B facility need not itself be a licensed pharmacy. Neither pathway turns a compounded drug into an FDA-approved finished product.
| Question | 503A | 503B |
|---|---|---|
| Core role | Licensed pharmacist or licensed physician; individual-patient prescription pathway under stated conditions | Registered outsourcing facility; compounding by or under a licensed pharmacist, with or without individual prescriptions under stated conditions |
| CGMP | Qualifying 503A drugs are exempt from federal CGMP requirements, while state standards and the prohibition on insanitary conditions still matter | The CGMP exemption is not available; qualifying outsourcing facilities must comply with CGMP |
| Oversight record to check | State pharmacy license and public discipline | FDA registration and inspection record plus applicable state records |
| FDA reporting | No parallel 503B facility registration, twice-yearly product reports, or mandatory 503B adverse-event reporting framework | Annual registration, product reports, and required reporting of serious unexpected adverse drug experiences |
| FDA product approval | No | No |
| What the category proves | A legal framework, not the quality of every preparation | A facility role and requirements, not approval of each product |
The 503A duplication condition needs patient-specific reading
Federal law limits regular or inordinate compounding of products that substantially duplicate commercially available drugs. A slogan such as custom dose is not enough. When the significant-difference exception is used, the prescriber must determine and document that a change in the compounded drug produces a significant difference for the identified patient. A general clinical preference and that legal determination are related questions, but they are not interchangeable.
On April 1, 2026, FDA said it did not intend to take action for that regular-or-inordinate condition when a compounder fills four or fewer prescriptions of the compounded drug product in a calendar month. That enforcement position is not approval or permission and does not excuse any other federal or state requirement.
The 503B supply role and current bulk-substance limit
Outsourcing facilities have a different supply role and additional federal duties. They are subject to CGMP, risk-based FDA inspection, adverse-event reporting, and product reports. Registration is useful information, but it is not an endorsement, a guarantee, or approval of a particular drug. FDA stated on April 1, 2026 that semaglutide and tirzepatide were not on the 503B bulks list or the drug shortage list. In general, a 503B facility may use a bulk drug substance only if the substance is on the bulks list or the drug made from it is on the shortage list at the time of compounding, distribution, and dispensing. Current lists and any applicable final or interim FDA policy must be checked. Any compounded preparation remains not FDA-approved and not brand-identical, and results vary.
Do not mix three different uses of need
A patient's clinical rationale, a 503A prescriber's documented significant-difference determination, and FDA's clinical-need determination for the 503B bulks list are separate concepts. One does not automatically establish another.
Verification and role clarity
- Match the legal pharmacy or facility name on the label to official records.
- Review active status, public discipline, FDA inspection material when applicable, and the prescription details.
- Ask which entity evaluates, prescribes, prepares, dispenses, answers product questions, and handles a recall.
- Do not assume that a clinic is the pharmacy or that a registration covers a different legal entity.
Primary and official source trail
Read each source for the exact product, population, date, method, and limitation. A source supports only the claim it actually studied or the policy it actually states.
Apply this checklist to New Hope
Every standard on this page is one we hold ourselves to: a $119 physician review with Dr. Anjmun Sharma, MD before any prescription decision, a named dispensing pharmacy you can verify for your location, transparent pricing with medication billed separately (compounded semaglutide from $166/month, tirzepatide from $233/month), and plain disclosure that compounded medications are not FDA-approved, not brand-identical, and that results vary. Telehealth care is available for eligible California patients.
See if you qualify, free 2-min quiz Check availability for your locationFrequently asked questions
What is the main difference between 503A and 503B?
Section 503A centers on preparations linked to prescriptions for identified patients. Section 503B creates a category of FDA-registered outsourcing facilities with a different production and distribution framework.
Is a 503B facility FDA-approved?
No. Facility registration does not mean FDA approved every product the facility prepares. Compounded drugs remain not FDA-approved.
Is 503B always better than 503A?
No. They serve different roles. The relevant path depends on the prescription, clinical need, law, and entity able to prepare or dispense the product.
How do I verify a pharmacy or facility?
Check the active state license and public disciplinary history. For an entity claiming 503B status, also check FDA's public facility and inspection records.
Does the clinic dispense a 503A preparation?
No. The clinic performs the evaluation and prescribes when appropriate. The licensed pharmacy prepares and dispenses a compounded prescription.
This article is educational and does not replace an individual medical evaluation. Do not start, stop, or change a medication without speaking with your health care professional.